Trial Profile
A Phase I Dose Escalation Study of Intermittent Oral OSI-906 Dosing in Patients With Advanced Solid Tumors.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Linsitinib (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Astellas Pharma
- 27 Mar 2019 According to a Life Molecular Imaging, Piramal imaging changed its name to Life Molecular Imaging.
- 03 Feb 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 02 Nov 2010 Planned End Date changed from 1 Nov 2010 to 1 Dec 2010 as reported by ClinicalTrials.gov.